NICE recommends tests for lung cancer mutation
NICE has recommended a number of tests and test strategies to help doctors target treatments more effectively for people with non-small-cell lung cancer (NSCLC), the most common form of lung cancer.
A package of tests and test strategies have been endorsed by the cost watchdog as they have been deemed to be both clinically and cost effective in determining whether NSCLC patients carry a particular genetic mutation.
The genetic mutation can produce an enzyme – epidermal growth factor receptor-tyrosine kinase (EGFR-TK). Its presence therefore dictates how best to treat the patient with NSCLC as patients can either be treated with the most appropriate chemotherapy or one that stops the EGFR-TK mutation from working.
NHS laboratories in England currently use tests to identify this mutation, however, there is no consensus on which laboratory test should be used.
NICE’s approved tests include Roche Molecular Systems’ cobas EGFR Mutation Test and Qiagen’s therascreen EGFR RGQ PCR Kit.
NICE advises on tests for lung cancer mutation (Pharma Times)
NICE issues draft recommendations for lung cancer drug (Press releases)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.